Nod-like receptor pyrin containing 3 (NLRP3) in the post-mortem frontal cortex from patients with bipolar disorder: A potential mediator between mitochondria and immune-activation
Related Experiment Video
Updated: Mar 30, 2026

Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
Helena Kyunghee Kim1, Ana Cristina Andreazza2, Nika Elmi1
1Departments of Psychiatry and Pharmacology, 1 King's College Circle, University of Toronto, Toronto, ON M5S 1A8, Canada.
Abstract:
Mitochondrial complex I dysfunction, oxidative stress and immune-activation are consistently reported in bipolar disorder (BD). Mitochondrial production of reactive oxygen species was recently linked to activation of an inflammatory redox sensor, the nod-like receptor family pyrin domain-containing 3 (NLRP3). Upon its activation, NLRP3 recruits apoptosis-associated speck-like protein (ASC) and caspase-1 to form the NLRP3-inflammasome, activating IL-1β. This study aimed to examine if immune-activation may be a downstream target of complex I dysfunction through the NLRP3-inflammasome in BD. Post-mortem frontal cortex from patients with BD (N = 9), schizophrenia (N = 10), and non-psychiatric controls (N = 9) were donated from the Harvard Brain Tissue Resource Center. Levels of NLRP3, ASC and caspase-1 were measured by western blotting, ELISA and Luminex. While we found no effects of age, sex or post-mortem delay, lower levels of complex I (F2,25 = 3.46, p < 0.05) and NDUFS7, a subunit of complex I (F2,25 = 4.13, p < 0.05), were found in patients with BD. Mitochondrial NLRP3 (F2,25 = 3.86, p < 0.05) and ASC (F2,25 = 4.61, p < 0.05) levels were higher in patients with BD. However, levels of caspase 1 (F2,25 = 4.13, p < 0.05 for both), IL-1β (F2,25 = 7.05, p < 0.01), IL-6 (F2,25 = 5.48, p < 0.05), TNFα (F2,25 = 7.14, p < 0.01) and IL-10 (F2,25 = 5.02, p < 0.05) were increased in both BD and schizophrenia. These findings suggest that immune-activation in the frontal cortex may occur both in patients with BD and schizophrenia, while complex I dysfunction and NLRP3-inflammasome activation may be more specific to BD.
Insights
Mitochondrial complex I dysfunction and NLRP3-inflammasome activation are linked to bipolar disorder (BD). Immune activation is observed in both BD and schizophrenia, suggesting complex I dysfunction and NLRP3-inflammasome activation may be specific to BD.
Area of Science:
- Neuroscience
- Immunology
- Genetics
Background:
- Bipolar disorder (BD) is consistently associated with mitochondrial complex I dysfunction, oxidative stress, and immune activation.
- Mitochondrial reactive oxygen species can activate the NLRP3 inflammasome, a key inflammatory pathway.
- The NLRP3 inflammasome pathway involves NLRP3, ASC, and caspase-1, leading to IL-1β activation.
Purpose of the Study:
- To investigate if immune activation in BD is a downstream effect of mitochondrial complex I dysfunction via the NLRP3 inflammasome.
- To compare these molecular changes in post-mortem frontal cortex samples from patients with BD, schizophrenia, and controls.
Main Methods:
- Western blotting, ELISA, and Luminex assays were used to measure protein levels.
- Analysis included levels of complex I subunits, NLRP3, ASC, caspase-1, IL-1β, IL-6, TNFα, and IL-10.
- Post-mortem frontal cortex tissues from patients with BD (N=9), schizophrenia (N=10), and controls (N=9) were analyzed.
Main Results:
- Lower levels of complex I and its subunit NDUFS7 were observed in patients with BD.
- Mitochondrial NLRP3 and ASC levels were elevated in patients with BD.
- Caspase-1, IL-1β, IL-6, TNFα, and IL-10 levels were increased in both BD and schizophrenia patients.
Conclusions:
- Immune activation in the frontal cortex is present in both bipolar disorder and schizophrenia.
- Mitochondrial complex I dysfunction and NLRP3-inflammasome activation appear to be more specific to bipolar disorder.
- These findings highlight potential distinct molecular pathways in psychiatric disorders.
Related Concept Videos
Bipolar Disorder
Long-term Depression
Calcium Ion Concentration Mechanism
If over...

